• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Reed-Lane

    Aphena Pharma Solutions

    Alcami

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    PCI Pharma Services

    Syngene

    Reed-Lane

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Rapid and Data Rich Chromatographic Method Development

    An overview of what to consider when developing chromatographic methods.

    Rapid and Data Rich Chromatographic Method Development
    Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina04.01.21
    The development of analytical methods for assay and impurity profiling of new chemical entities (NCEs) in pharmaceutical analysis is a complex task that no single method development approach can satisfy. New drug substance high performance liquid chromatography (HPLC) methods must resolve a wide range of potential degradants and manufacturing impurities while being appropriately sensitive, selective, precise, accurate, and robust. An unbiased and well-designed approach is key to rapidly developing optimal chromatographic conditions based on data-rich analysis.

    This article offers an overview of what to consider when developing chromatographic methods and how a step-by-step, unbiased approach can pay off in reduced timelines and costs with robust results.

    Method development matters
    The goal of method development is to design an HPLC method that operates reliably in a good manufacturing practice (GMP) environment. In the early stage of method development, it is important to understand analyte behavior in both the mobile and stationary phases. Be aware of the functional groups on the analyte, and whether the compound is acidic, basic, or neutral. Reactive functional groups and other properties may affect solubility, stability, and column retention. Comprehensive chemical knowledge can help elucidate critical method attributes and aid in troubleshooting if poor performance occurs.
    Though understanding the chemical properties of the compound is crucial for method development, performing unbiased and systematic screening activities is essential to developing a robust method predicated on a wealth of data.  

    Common method development pitfalls
    While no single answer exists for all development processes, there are some common pitfalls to avoid:
    1. Letting “educated guesswork” drive method development. Do not expect an approach that showed success for a similar compound to be appropriate for a new analyte—each compound presents a unique impurity profile, degradants, and residual process intermediates that require special attention. Although chemical properties (such as acidic or basic groups) have a role in designing analytical methods, a practical and objective procedure should be pursued. Attempting to develop an appropriate method while minimizing your method development tools (see below) by relying on “educated guesswork” can lead to an inefficient iterative process of method tuning, while producing little improvement. 
    2. Not establishing goals and reasonable expectations. Before beginning a method development project, define the goals for resolution, specificity, sensitivity, and other chromatographic properties. These can be set according to the phase of development for the drug compound. Consider potential degradation pathways, process impurities, and stereochemistry of the compound prior to initiating method development to help identify related substances that may be difficult to chromatograph and detect. It may be more efficient—for timelines and costs—to utilize several simple and robust methods, as opposed to developing a single overly complicated method.
    3. Delaying robustness studies (or, settling for a method that just works). Robustness studies ensure that the method performs reliably under minor variations. Observing chromatographic changes during a systematic method development process can inherently establish method robustness. Understanding which parameters are critical to quality during the development process will prevent validation of methods that operate on the fringes of acceptability. Building robustness into the early method development process can ultimately save time and money over the lifecycle of the drug, from the early stages through commercialization.   
    Method development tools
    Detectors
    Before comprehensively evaluating the chemical interactions of the analyte with the HPLC phases, the detection mechanism can be a significant factor to consider. Different detectors can have vastly different sensitivity attributes and should be chosen based on chemical properties of the analytes. For compounds with a UV-chromophore, a photo diode array detector (PDA) assists with selecting the ideal detection wavelength for the active and its related substances. A multi-detector setup using both a PDA and a universal detector ensures that all species are captured. Common universal detectors include charged aerosol detectors (CAD), evaporative light scattering detectors (ELSD), refractive index detectors (RID), and mass spectrometers. Fluorescence detectors may also be used if chemical properties allow for this unique detection.

    Columns (Stationary Phase)
    A variety of commercial column chemistries are available that can provide different elution profiles (or selectivity) for a mixture of compounds. While C18 phases are common in the industry, advancements in the last few decades have produced more unique phases such as pentafluorophenyl (PFP) or phenyl-hexyl phases that may provide enhanced resolution. Among the major phase classifications, there are other manufacturer-related features to consider such as silica porosity, end capping, core-shell technology, and charged surface hybrid structures.

    For example, pore size can have a large impact on the resolution of an analyte mixture, depending on the size and structure of the compounds. Carbon load may also be considered if the compound or matrix retains too long (or not long enough).

    Ideally, an HPLC equipped with multiple column compartments is utilized to produce a rich source of data which allows for comparison of resolution between analytes and impurities across an array of screened column phases. After a lead set of columns are identified, a forced degradation analysis can further aid in selection of a superior column chemistry, and later the appropriate dimensions. 

    Solvent Selection (Mobile Phase)
    Concomitantly with column screening, an HPLC setup with multiple solvent lines can afford advantages to rapid method development. Evaluating various organic solvents during column screening provides copious information about the selectivity of the analytes with each stationary and mobile phase combination. The solvent selectivity triangle may be consulted when evaluating the advantages of various strong eluents and their influence on selectivity. Methanol, tetrahydrofuran, and acetonitrile are commonly recommended strong solvents with complementary acidic, basic, and polar natures. When selecting mobile phases to screen, first verify that combinations of weak and strong solvents are miscible, and any buffering salts are fully soluble. Additionally, the UV-cutoff of the mobile phase solvents should be suitable for the detection wavelength to avoid baseline instability and poor sensitivity.    

    Furthermore, systematic changes to temperature, gradient, and mobile phase pH help elucidate the interactions of analytes on the column—and add to method robustness characterization! These factors may be considered simultaneously while screening mobile phases. Together, the mobile phase and column screening approach provides a wealth of objective data regarding resolution, retention, peak shape, and sensitivity.

    Mobile Phase Modifiers
    While phosphoric acid, formic acid, or trifluoroacetic acid (TFA) are commonly added modifiers, others may be necessary to establish resolution of analytes. Make decisions on mobile phase additives based on analyte structure properties. For example, acidic modifiers (or low-pH buffers) can protonate surface silanols and alter cationic interactions, reducing peak tailing in certain circumstances.

    Also, consider the detection mechanism. If a universal detector is used, avoid non-volatile additives (such as sodium or phosphate salts). In low-UV detection methods, TFA and formic acid may not be appropriate for adequate sensitivity.

    Besides acidic modifiers, other common modifiers include:
    • Bases: Even with a good track record in LC methods, bases can be a challenge because they may modify the overall charge state of the analyte. Operating a method above the pKa of a basic species is useful for stable compounds when there is a need to increase the on-column retention. Organic bases are not widely used in the pharmaceutical industry for developing assay-related substance methods because of a tendency for molecules to hydrolyze, or be reactive, at high pH. The pH limit of the column must also be considered if using a basic modifier.
    • Ion-pairing agents: In cases where separation remains elusive, an ion-pairing agent may be necessary. Ion-pairing agents, such as TFA, have a strong affinity for oppositely charged compounds, minimizing undesirable secondary interactions (resulting in tailing) or improving retention. Other ion-pairing agents such as alkyl sulfonic acids have an ionic end and a non-polar tail that is strongly retained by the hydrophobic column stationary phase. This leaves a charged functional group available to modify interactions of the analyte with the stationary phase and offers greater retention of oppositely charged species. Certain ion-pairing additives are not a first choice in development because of increased equilibration times, higher UV-cutoffs, and permanent alteration to columns.
    • Buffers: As mobile phases, buffers can control the ionization state of compounds. When optimized for pH and concentration, they can alter selectivity of analytes and improve resolution. The stability and pKA of compounds need to be considered when selecting a suitable buffer system to avoid rapid degradation during analysis or peak splitting due to the compound being in multiple charge states.
    A systematic approach
    When starting method development, generic gradient and detection screening (detection wavelength selection and injection volume) is often a first step. This ensures adequate sensitivity and retention are achieved before initiating an exhaustive column and mobile phase screen. Intermediates and impurity markers are blended into a “resolution solution” to provide the most data during screening. Forced degradation early in the process can also be performed, and is particularly helpful when related substances are not yet characterized or available.

    Mobile phase screening, including THF, methanol and acetonitrile can then be carried out based on the solvent selectivity triangle. Various buffered mobile phases and mobile phase additives are also tested. Several promising columns generally emerge from this method development workflow. Those columns are then taken through gradient ramping, temperature screening, and flow rate adjustments. The final method is then optimized and ready for pre-validation activities, which includes the final forced degradation evaluation.

    Robust methods deliver
    Using a critical approach to column and mobile phase selection screening, with systematic, stepwise optimization to work robustness into methods from early stages will pay off across the life of a program. Rapid and data rich method development delivers sensitive, selective, precise, accurate, and robust methods that today’s manufacturers can rely on. 

    Method Development Without Impurity Markers
    When there are no impurity markers available, like in the case of new drug candidates, several options can be considered:

    Dirty lots: The earliest batches—where the manufacturing process still needs developing—are taken and called dirty lots. They are used in the column screening approach, in addition to the forced degradation studies. At Cambrex, mass spectrometry detection is also used to provide more information about the impurity profiles and enable peak tracking.

    Forced degradation: During a column screening approach, forced degradation studies are incorporated to verify resolution of key related species. This includes acid, base, photo, oxidative, and thermal stress.

    Mass spectrometry: Pharmaceutical development is complex. If available, additional detection via mass spectrometry is often an advantage (though it cannot be used in some methods, with non-volatile mobile phase components). By incorporating column screening and mass spectral detection, various key peaks can be tracked, enhancing the overall screening approach. 



    Dr. Daniel Kirschner is executive director of analytical services at the Cambrex Durham, NC site specializing in analytical services for drug substances and drug products at all stages of the clinical and commercial development lifecycle.
    Related Searches
    • Analytical Services
    • Bioanalytical Services
    • R&D
    • Laboratory Testing

    Related Features

    • R&D
      Small Innovators & Niche CROs

      Small Innovators & Niche CROs

      Smaller CROs have the opportunity to provide a niche approach to its clients, particularly smaller sponsors who have shared synergies.
      Neil Goodman, David Bruce and Mohamed El Malt, Europital 04.01.21

    • Laboratory Testing
      Focus on Science

      Focus on Science

      How to maximize lab performance and value through comprehensive equipment management.
      Rohit Shroff, Senior Vice President, Global Lab Products, Avantor 04.01.21

    • Laboratory Testing | R&D
      How Modern Near-Infrared Came to Be

      How Modern Near-Infrared Came to Be

      First region outside the visible to be discovered and last to be utilized.
      Gary E. Ritchie, Contributing Writer 04.01.21


    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20


    • Laboratory Testing
      Necessary, Appropriate, Valid: A mantra for facility managers creating complete health strategies

      Necessary, Appropriate, Valid: A mantra for facility managers creating complete health strategies

      The challenge of maintaining colony health; the importance of health monitoring
      Emmanuel Gomas, European Services Manager, Envigo 11.13.18

    • Bioanalytical Services
      Viral Contaminant Testing in Biopharma Manufacturing

      Viral Contaminant Testing in Biopharma Manufacturing

      There is no single test to detect all potential viral contaminants in biopharmaceutical manufacturing.
      Richard Adair, Virology Manager, SGS Life Sciences, Glasgow, UK 11.13.18

    • Clinical Trials | R&D
      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Cost pressures on drug development are driving the search for savings and efficiencies—but efforts need to be integrated if t
      ICON plc 10.10.18


    • Drug Development | Information Technology | R&D
      CRO Industry Update: Big Data Drives Drug Development Efforts

      CRO Industry Update: Big Data Drives Drug Development Efforts

      With growth in virtual trials and RWE, the clinical development landscape may never look the same
      Kristin Brooks, Managing Editor 05.11.18

    • Analytical Services | QA/QC
      Newsmakers: LSNE

      Newsmakers: LSNE

      LSNE Expands Capabilities and QC Laboratory Space
      Tim Wright, Editor 05.08.18

    • R&D
      A Blueprint to Unify Clinical Operations

      A Blueprint to Unify Clinical Operations

      Fast-growing clinical research organization speeds study execution and improves quality
      Jim Reilly, VP of Clinical Market Strategy, Veeva Systems 05.08.18


    • R&D
      Newsmakers: Charles River

      Newsmakers: Charles River

      Charles River Expands
      Kristin Brooks, Managing Editor 05.07.18

    • Analytical Services | Laboratory Testing
      The Time Has Come

      The Time Has Come

      Looking at the change from USP <231> to USP <232> and <233> and what it means.
      Nikki Schopp, Assistant Manager, Analytical Laboratory Services at SGS Life Sciences 04.10.18

    • Analytical Services
      Getting from Risk Assessment to Regulatory Submission

      Getting from Risk Assessment to Regulatory Submission

      Taking the next steps from risk assessment through method development, method validation and testing to the updating of an an
      Anthony DeStefano and Thomas Kester, Recordati Rare Diseases, Inc. 03.09.18

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Executive Moves: Novavax
    • Ensuring Pharma Manufacturing Quality
    • Sanofi Invests In Cutting Edge Vax Production Site In Singapore
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login